Most kinds of CMT come from a problem in a single gene. Repairing that faulty...
Particles on a Mission: Can Nanoparticles Solve One of CMT’s Largest Hurdles?
Can nanoparticles solve one of CMT’s largest hurdles? A team in Cyprus is testing nanoparticle “mail carriers” designed to deliver genetic therapies directly into Schwann cells.
This Genetic Tape Could Silence the Cause of CMT2E
What happened when CMTA-supported scientists at the University of Miami applied a piece of genetic tape to the gene mutation that causes CMT2E?
CMTA-STAR Alliance Partner Doses First CMT2S Patient
CMTA-STAR Alliance Partner Doses First CMT2S Patient
Accelerating Genetic Therapy for CMT4B1: A CMTA Research Update
With CMTA’s support, researchers at San Raffaele Scientific Institute in Milan, Italy, led by Alessandra...
CMTA’s $300K Investment in CRISPR for CMT2A
The Charcot-Marie-Tooth Association (CMTA) is investing $300,000 in a groundbreaking gene editing research project at...
CMTA’s $300K Investment in CRISPR for CMT2A
CMTA announced a $300,000 CMTA-STAR investment supporting CRISPR-based gene editing research aimed at selectively silencing disease-causing MFN2 mutations in CMT2A.
CMTA Invests $423K to Accelerate CMT Diagnostics and Gene Discovery
CMTA announced today a $423,000 investment to address diagnostic gaps and drive new CMT gene...
Nervosave: Shaping the Future of Genetic Therapy for CMT1A
What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, a France-based biotech company, is...
CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT
CMTA announced an investment of over $500,000 supporting international research projects focused on demyelinating forms of CMT, including CMT1A and CMT1B.
